Donald Cutlip

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Troponin criteria for myocardial infarction after percutaneous coronary intervention
    Victor Novack
    Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
    Arch Intern Med 172:502-8. 2012
  2. ncbi request reprint Drug-eluting stent era: will we improve 5-year outcomes?
    Donald E Cutlip
    Interventional Cardiology Section, Beth Israel Deaconess Medical Center, Harvard Clinical Research Institute, Harvard Medical School, Boston, Massachusetts, USA
    Coron Artery Dis 17:681-4. 2006
  3. ncbi request reprint Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Cardiac enzyme elevation after successful percutaneous coronary intervention is not an independent predictor of adverse outcomes
    Donald E Cutlip
    Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Clinical Research Institute, Boston, MA, USA
    Circulation 112:916-22; discussion 922. 2005
  4. ncbi request reprint Clinical end points in coronary stent trials: a case for standardized definitions
    Donald E Cutlip
    Harvard Clinical Research Institute, Harvard Medical School, 930 Commonwealth Avenue, Boston, MA 02215, USA
    Circulation 115:2344-51. 2007
  5. ncbi request reprint Drug-eluting stent era: will we improve 5-year outcomes?
    Donald E Cutlip
    Interventional Cardiology Section, Beth Israel Deaconess Medical Center, Harvard Clinical Research Institute, Harvard Medical School, Boston, Massachusetts 02215, USA
    Coron Artery Dis 17:289-92. 2006
  6. ncbi request reprint Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction
    Donald E Cutlip
    Interventional Cardiology Section, Beth Israel Deaconess Medical Center, Boston, Massacusetts 02215, USA
    Am J Cardiol 92:977-80. 2003
  7. doi request reprint Autopsy validation study of the academic research consortium stent thrombosis definition
    Donald E Cutlip
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    JACC Cardiovasc Interv 4:554-9. 2011
  8. doi request reprint In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry
    Victor Novack
    Harvard Clinical Research Institute, Boston, Massachusetts, USA
    JACC Cardiovasc Interv 2:767-75. 2009
  9. pmc A pilot study examining the severity and outcome of the post-cardiac arrest syndrome: a comparative analysis of two geographically distinct hospitals
    Michael W Donnino
    Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Circulation 126:1478-83. 2012
  10. ncbi request reprint Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial
    Duane S Pinto
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 48:32-6. 2006

Research Grants

Collaborators

Detail Information

Publications53

  1. doi request reprint Troponin criteria for myocardial infarction after percutaneous coronary intervention
    Victor Novack
    Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
    Arch Intern Med 172:502-8. 2012
    ....
  2. ncbi request reprint Drug-eluting stent era: will we improve 5-year outcomes?
    Donald E Cutlip
    Interventional Cardiology Section, Beth Israel Deaconess Medical Center, Harvard Clinical Research Institute, Harvard Medical School, Boston, Massachusetts, USA
    Coron Artery Dis 17:681-4. 2006
    ....
  3. ncbi request reprint Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Cardiac enzyme elevation after successful percutaneous coronary intervention is not an independent predictor of adverse outcomes
    Donald E Cutlip
    Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Clinical Research Institute, Boston, MA, USA
    Circulation 112:916-22; discussion 922. 2005
  4. ncbi request reprint Clinical end points in coronary stent trials: a case for standardized definitions
    Donald E Cutlip
    Harvard Clinical Research Institute, Harvard Medical School, 930 Commonwealth Avenue, Boston, MA 02215, USA
    Circulation 115:2344-51. 2007
    ..Although most clinical trials of coronary stents have measured nominally identical safety and effectiveness end points, differences in definitions and timing of assessment have created confusion in interpretation...
  5. ncbi request reprint Drug-eluting stent era: will we improve 5-year outcomes?
    Donald E Cutlip
    Interventional Cardiology Section, Beth Israel Deaconess Medical Center, Harvard Clinical Research Institute, Harvard Medical School, Boston, Massachusetts 02215, USA
    Coron Artery Dis 17:289-92. 2006
    ....
  6. ncbi request reprint Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction
    Donald E Cutlip
    Interventional Cardiology Section, Beth Israel Deaconess Medical Center, Boston, Massacusetts 02215, USA
    Am J Cardiol 92:977-80. 2003
    ..20). Patients receiving early tirofiban treatment were more likely to achieve complete (>70%) ST-segment resolution at 90 minutes (69% vs 44%, p = 0.07)...
  7. doi request reprint Autopsy validation study of the academic research consortium stent thrombosis definition
    Donald E Cutlip
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    JACC Cardiovasc Interv 4:554-9. 2011
    ..This study sought to validate the sensitivity and specificity of the Academic Research Consortium's (ARC) classification of stent thrombosis...
  8. doi request reprint In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry
    Victor Novack
    Harvard Clinical Research Institute, Boston, Massachusetts, USA
    JACC Cardiovasc Interv 2:767-75. 2009
    ..The aim of this study was to compare outcomes among unselected patients undergoing percutaneous coronary intervention (PCI) with either sirolimus-eluting (SES) or paclitaxel-eluting stents (PES)...
  9. pmc A pilot study examining the severity and outcome of the post-cardiac arrest syndrome: a comparative analysis of two geographically distinct hospitals
    Michael W Donnino
    Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Circulation 126:1478-83. 2012
    ..We tested whether hospital-independent factors would account for the difference in outcome between 2 geographically distinct hospitals...
  10. ncbi request reprint Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial
    Duane S Pinto
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 48:32-6. 2006
    ....
  11. ncbi request reprint Effect of diabetes mellitus on five-year clinical outcomes after single-vessel coronary stenting (a pooled analysis of coronary stent clinical trials)
    Tobias T Lee
    Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 98:718-21. 2006
    ....
  12. ncbi request reprint Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy
    Duane S Pinto
    TIMI Study Group and the Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, 185 Pilgrim Rd, Boston, MA 02115, USA
    Circulation 114:2019-25. 2006
    ..We also hypothesized that in addition to PPCI delays, patient risk factors would significantly modulate the relative survival advantage of PPCI over fibrinolysis...
  13. ncbi request reprint Stent thrombosis in randomized clinical trials of drug-eluting stents
    Laura Mauri
    Brigham and Women s Hospital, Boston, USA
    N Engl J Med 356:1020-9. 2007
    ..Definitions of stent thrombosis that have been used in clinical trials of drug-eluting stents have been restrictive and have not been used in a uniform manner...
  14. ncbi request reprint Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    N Engl J Med 356:998-1008. 2007
    ..Such studies have been inconclusive because of their insufficient size, the use of historical controls, a limited duration of follow-up, and a lack of access to original source data...
  15. doi request reprint Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the evaluation of drug eluting stents and ischemic events reg
    Allen Jeremias
    Division of Cardiovascular Medicine, Stony Brook University Medical Center, Stony Brook, NY, USA
    Circulation 118:632-8. 2008
    ....
  16. ncbi request reprint Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation
    Gregg W Stone
    Columbia University Medical Center, The Cardiovascular Research Foundation, 111 E 59th St, 11th Floor, New York, NY 10022, USA
    Circulation 115:2842-7. 2007
    ..We hypothesized that the prevention of restenosis-related adverse events by drug-eluting stents might offset some or all of the excess risk from ST...
  17. ncbi request reprint Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial
    Marie Claude Morice
    Institut Cardiovasculaire Paris Sud, Massy, France
    J Am Coll Cardiol 50:1299-304. 2007
    ..This study examined the clinical outcomes at 5 years in RAVEL (A Randomized Comparison of a Sirolimus-Eluting Stent With a Standard Stent for Coronary Revascularization), the first controlled trial of drug-eluting stents...
  18. ncbi request reprint Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients
    Ramon Kumar
    Department of Medicine, Cardiology Division, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Am J Cardiol 100:1187-91. 2007
    ....
  19. doi request reprint Reduction in sex-based mortality difference with implementation of new cardiology guidelines
    Victor Novack
    Department of Medicine, Soroka University Medical Center, Beer Sheva, Israel
    Am J Med 121:597-603.e1. 2008
    ....
  20. doi request reprint Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients
    Alanna Coolong
    Division of Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 117:790-7. 2008
    ..Although MACE rates are reduced significantly by the use of embolic protection devices (EPDs), neither the level of baseline risk nor the benefit provided by EPDs has been well characterized...
  21. doi request reprint Differential outcomes after sirolimus-eluting stent implantation: comparing on-label versus off-label patients in the 'real world'
    Allen Jeremias
    Division of Cardiovascular Medicine, Stony Brook University Medical Center, Stony Brook, NY 11794, USA
    Coron Artery Dis 19:111-5. 2008
    ..This study examined the performance of SES in a 'real world' setting by comparing the outcomes of trial-eligible versus ineligible patients undergoing percutaneous coronary intervention...
  22. doi request reprint Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: results of a multicenter case-control study with 145 thrombosis events
    Michael J Rinaldi
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Am Heart J 155:654-60. 2008
    ....
  23. doi request reprint Long-term results of carotid stenting versus endarterectomy in high-risk patients
    Hitinder S Gurm
    University of Michigan School of Medicine, Ann Arbor, USA
    N Engl J Med 358:1572-9. 2008
    ..We now report the 3-year results...
  24. doi request reprint Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial
    Gregg W Stone
    Columbia University Medical Center, The Cardiovascular Research Foundation, 111 E 59th St, 11th Floor, New York, NY 10022, USA
    JAMA 299:1903-13. 2008
    ....
  25. pmc The Claudication: Exercise Vs. Endoluminal Revascularization (CLEVER) study: rationale and methods
    Timothy P Murphy
    Rhode Island Hospital Vascular Disease Research Center and Brown Medical School Department of Diagnostic Imaging, Providence, RI 02903, USA
    J Vasc Surg 47:1356-63. 2008
    ....
  26. ncbi request reprint Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial
    Giora Weisz
    Cardiovascular Research Foundation and Columbia University Medical Center, New York, New York 10032, USA
    J Am Coll Cardiol 47:1350-5. 2006
    ..The purpose of this study was to examine the two-year clinical outcomes in patients enrolled in the Sirolimus-Eluting Stent in De Novo Native Coronary Lesions (SIRIUS) study...
  27. ncbi request reprint Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: results from the SAFER trial
    David J Cohen
    Harvard Clinical Research Institute, Boston, Massachusetts, USA
    J Am Coll Cardiol 44:1801-8. 2004
    ..The goal of this research was to determine the incremental cost and cost-effectiveness of embolic protection in patients undergoing percutaneous revascularization (PCI) of diseased saphenous vein bypass grafts (SVGs)...
  28. ncbi request reprint Protected carotid-artery stenting versus endarterectomy in high-risk patients
    Jay S Yadav
    Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    N Engl J Med 351:1493-501. 2004
    ..Stenting with the use of an emboli-protection device is a less invasive revascularization strategy than endarterectomy in carotid-artery disease...
  29. ncbi request reprint Utility of the Safe-Cross-guided radiofrequency total occlusion crossing system in chronic coronary total occlusions (results from the Guided Radio Frequency Energy Ablation of Total Occlusions Registry Study)
    Donald S Baim
    Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120 1613, USA
    Am J Cardiol 94:853-8. 2004
    ..Based on these data, the device has been approved in Europe and was recently (January 2004) granted 510K clearance by the Food and Drug Administration...
  30. ncbi request reprint Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures
    Allen Jeremias
    Harvard Clinical Research Institute, Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Am Coll Cardiol 44:1210-4. 2004
    ..This study was designed to evaluate the effect of periprocedural myocardial infarction (MI) on mortality according to success of the stent procedure...
  31. ncbi request reprint Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials
    Donald E Cutlip
    Harvard Clinical Research Institute, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Circulation 110:1226-30. 2004
    ....
  32. ncbi request reprint Effects of stent length and lesion length on coronary restenosis
    Laura Mauri
    Division of Clinical Biometrics, Brigham and Women s Hospital, 1620 Tremont Street, Boston, MA 02120, USA
    Am J Cardiol 93:1340-6, A5. 2004
    ..This analysis supports a conservative approach of matching stent length to lesion length to reduce the risk of restenosis with bare metal stents...
  33. ncbi request reprint Drug-eluting stent task force: final report and recommendations of the working committees on cost-effectiveness/economics, access to care, and medicolegal issues
    John McB Hodgson
    MetroHealth Medical Center, Cleveland, Ohio 44109, USA
    Catheter Cardiovasc Interv 62:1-17. 2004
    ..The Task Force trusts that this report will be of value to the diverse constituencies involved with introduction of this important new technology...
  34. ncbi request reprint Stent thrombosis after successful sirolimus-eluting stent implantation
    Allen Jeremias
    Section of Interventional Cardiology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass, USA
    Circulation 109:1930-2. 2004
    ..5% to 1.9% of patients with bare metal stents. The incidence of ST with drug-eluting stents is less well studied, particularly among patients outside of clinical trials...
  35. ncbi request reprint Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials
    Donald E Cutlip
    Harvard Clinical Research Institute, Boston, Massachusetts 02215, USA
    J Am Coll Cardiol 40:2082-9. 2002
    ..We sought to evaluate clinical restenosis in a large population of patients who had undergone coronary stent placement...
  36. ncbi request reprint Effect of gender on in-hospital and one-year outcomes after contemporary coronary artery stenting
    Manish S Chauhan
    Lahey Clinic Medical Center, Burlington, Massachsetts 01805, USA
    Am J Cardiol 95:101-4. 2005
    ....
  37. ncbi request reprint Cutting balloon angioplasty for the prevention of restenosis: results of the Cutting Balloon Global Randomized Trial
    Laura Mauri
    Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 90:1079-83. 2002
    ..CB angioplasty should be reserved for difficult lesions in which controlled dilatation is believed to provide a better acute result compared with balloon angioplasty alone...
  38. ncbi request reprint Geographical differences in the rates of angiographic restenosis and ischemia-driven target vessel revascularization after percutaneous coronary interventions: results from the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) Trial
    Mandeep Singh
    Division of Internal Medicine and Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 47:34-9. 2006
    ..In the absence of a definitive clinical trial to support this view, how should the prudent, cutting-edge cardiologist proceed?..
  39. ncbi request reprint Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials
    Laura Mauri
    Brigham and Women s Hospital, Boston, MA 02116, USA
    Circulation 112:2833-9. 2005
    ..We hypothesized that mean in-stent late loss might be a more stable estimator of restenosis propensity across such studies...
  40. ncbi request reprint A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents
    Christian Spaulding
    Assistance Publique Hôpitaux de Paris Cochin Hospital, Paris 5 Medical School René Descartes University and INSERM Unité 780 Avenir, Paris
    N Engl J Med 356:989-97. 2007
    ..The long-term safety of drug-eluting stents has been questioned recently...
  41. ncbi request reprint Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts
    Donald S Baim
    Division of Cardiovascular Diseases, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Circulation 105:1285-90. 2002
    ..We report the first multicenter randomized trial to evaluate use of a distal embolic protection device during stenting of such lesions...
  42. ncbi request reprint Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents
    Laura Mauri
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Am J Cardiol 95:1140-5. 2005
    ..Longer stent-to-lesion length strategies should be used only when a shorter stent is likely to result in incomplete lesion coverage and edge dissection, a strong determinant of stent thrombosis...
  43. ncbi request reprint Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents
    Laura Mauri
    Brigham and Women s Hospital, Boston, Mass 02116, USA
    Circulation 111:321-7. 2005
    ..Observed rates of restenosis after drug-eluting stenting are low (<10%). Identification of a reliable and powerful angiographic end point will be useful in future trials...
  44. ncbi request reprint Rheolytic thrombectomy and platelet glycoprotein IIb/IIIa blockade for stent thrombosis
    Stephane Rinfret
    Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Catheter Cardiovasc Interv 57:24-30. 2002
    ..A combined approach of rheolytic thrombectomy with adjunctive GP IIb/IIIa blockade was highly effective in resolving stent thrombosis and was associated with favorable acute and long-term outcomes...
  45. ncbi request reprint Determinants of 30-day adverse events following saphenous vein graft intervention with and without a distal occlusion embolic protection device
    Gregory R Giugliano
    Division of Cardiology, Brigham and Women s Hospital, One Brigham Circle, Boston, MA 02115, USA
    Am J Cardiol 95:173-7. 2005
    ....
  46. ncbi request reprint Incidence and predictors of late total occlusion following coronary stenting
    Pinak B Shah
    Cardiovascular Division, St Elizabeth s Medical Center, Boston, Massachusetts 02135, USA
    Catheter Cardiovasc Interv 60:344-51. 2003
    ..004), longer stent length (P < 0.001), and smaller preprocedure MLD (P = 0.012) were independent predictors of total occlusion following coronary stenting...
  47. ncbi request reprint Comparison of rotational atherectomy with conventional balloon angioplasty in the prevention of restenosis of small coronary arteries: results of the Dilatation vs Ablation Revascularization Trial Targeting Restenosis (DART)
    Laura Mauri
    Swedish Hospital, Seattle, Wash, USA
    Am Heart J 145:847-54. 2003
    ..We report on a multicenter, randomized, blinded end point trial comparing rotational atherectomy with balloon angioplasty in the prevention of restenosis of obstructed small coronary arteries...
  48. ncbi request reprint Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study
    Ian T Meredith
    Monash Medical Centre and Monash University, Melbourne, Australia
    Am J Cardiol 100:56M-61M. 2007
    ..The treatment of patients with symptomatic CAD due to de novo lesions in native coronary arteries with the Endeavor ZES has sustained clinical benefits to 4 years, with very low rates of MACE and TLR...
  49. ncbi request reprint Risk of target lesion revascularization after coronary stenting in patients with and without chronic kidney disease
    David Charytan
    Department of Medicine, Brigham and Women s Hospital, Renal Division, Clinical Biometrics, 1 Brigham Circle, 3rd Floor, Boston, MA 02115, USA
    Nephrol Dial Transplant 22:2578-85. 2007
    ..Whether mild to moderate chronic kidney disease (CKD) is associated with a similarly increased need for short or long-term target lesion revascularization (TLR) following coronary stenting is uncertain...
  50. ncbi request reprint Drug eluting stents for ST-elevation myocardial infarction: risk and benefit
    Jason Ryan
    Beth Israel Deaconess Medical Center and Harvard Medical School, 1 Deaconess Road, Boston, MA 02215, USA
    J Thromb Thrombolysis 24:293-9. 2007
    ..This review with discuss the theoretical risks and benefits of DES for STEMI, the available data regarding their use, and the areas where future studies are needed...
  51. ncbi request reprint Obesity and clinical restenosis after coronary stent placement
    Jamal S Rana
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Am Heart J 150:821-6. 2005
    ..Obesity has been associated with improved clinical outcomes after percutaneous coronary intervention--"obesity paradox."..
  52. ncbi request reprint Relationship of chronic kidney disease to cardiovascular death and myocardial infarction following coronary stenting
    David M Charytan
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02120, USA
    J Nephrol 19:764-70. 2006
    ....
  53. ncbi request reprint Gender-specific outcomes after sirolimus-eluting stent implantation
    Emilia Solinas
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
    J Am Coll Cardiol 50:2111-6. 2007
    ..We examined the impact of gender on outcomes of patients undergoing percutaneous coronary intervention using sirolimus-eluting stents (SES)...

Research Grants1

  1. Claudication Exercise vs Endoluminal Revascularization
    Donald Cutlip; Fiscal Year: 2007
    ..Recruitment will be done over 28 months and patients will be followed for 18 months; the total study duration will be 5 years. ..